ttfields for lung cancer vs meso - is it the same thing or different

Not a medical professional so take this for what it's worth from the legal side, but I've sat across from hundreds of meso patients over 20 years and TTFields comes up more and more now. What I can tell you is the FDA approval pathway was actually separate for meso versus lung cancer, which matters more than people realize.

For lung cancer the approval came through a few years before the meso indication. The LUNAR trial specifically looked at non-small cell lung cancer. The STELLAR trial was the meso data, published around 2019 or so, and that's what got it the FDA breakthrough designation for pleural meso. So the mechanisms are similar, disrupting cell division with electric fields rather than killing cells chemically the way chemo does, but the application and what they're watching for are genuinely different.

Stage II post-surgery in December is actually a situation where I've seen patients have real conversations about this as maintenance or combination therapy. Whether it makes sense alongside your current chemo plan is something your oncologist would know better than anyone, but getting a second opinion at a dedicated mesothelioma center, somewhere like Brigham and Women's or MD Anderson or Penn, could clarify whether the STELLAR trial protocol applies to your specific situation.

From a purely practical standpoint, insurance coverage for TTFields in meso has gotten better since that FDA designation but it's still not automatic. Worth asking your care team about the prior authorization process early.

Please consult an attorney and your own medical team for your specific situation, but I hope some of that context helps.

Not exactly the same, even though the device looks identical. The FDA approved TTFields for pleural mesothelioma back in 2019 under the brand name Optune Lua, and that approval was specifically based on the STELLAR trial data, which showed median overall survival around 18 months when combined with standard chemo. The lung cancer indication came earlier and involved different frequency settings, so your oncologist should be dialing in parameters specific to meso, not just borrowing the lung cancer protocol.

What it actually does is pretty different from chemo. It's an electric field delivered through patches on your torso that disrupts cell division, so it's targeting rapidly dividing cancer cells without the same systemic toxicity you'd get from platinum-based regimens. Not zero side effects, skin irritation is real and can be significant, but the mechanism is genuinely different.

Here's where your timing actually matters. Stage II post-surgery in December puts you in a window where the combination approach has shown the most promise in the meso-specific literature. The STELLAR trial enrolled patients in your general situation.

The jurisdiction piece I'd flag, and this applies to the legal side too, is that coverage approval for TTFields varies pretty significantly by insurer and state, and that can affect what's practically available to you. Some of my clients have had to go through a formal appeals process before getting coverage.

If you haven't already, getting into a meso-specific center rather than a general oncology practice would be worth it. The experience gap between general oncologists and meso specialists on this particular device is real.

Please consult an attorney for your specific situation if you have questions about the legal side of your diagnosis.

Not exactly the same, though the underlying mechanism is shared. TTFields works by delivering low intensity electrical fields that disrupt cell division, so it's not cytotoxic the way chemo is. It doesn't poison cells, it interferes with mitosis. The practical effect is that rapidly dividing cancer cells are more vulnerable to it than normal tissue.

For lung cancer the device got FDA clearance back in 2019, so there's a few more years of real world data. For pleural meso specifically the STELLAR trial published results showing median overall survival around 18 months when combined with standard chemotherapy, which got a lot of attention in the meso community because those numbers were meaningful. The FDA cleared it for meso in 2019 as well, so it's not experimental territory at this point.

The application is actually different between the two because of anatomy. Meso patients wear the transducer arrays on the chest and back rather than the lung placement configuration, and honestly getting the electrode placement right matters a lot. We had a client in 2021 whose compliance rate was below 50 percent because of fit issues and his oncologist at a major cancer center in Houston adjusted the whole setup.

Stage II post surgery is actually a situation where some oncologists feel TTFields may add value as adjuvant treatment, but that depends heavily on your specific margins, your overall functional status, and what your surgeon documented. Please do consult an attorney for your specific situation if any of this connects to an occupational exposure claim, because timing matters for those filings. But on the medical side, talking to a meso specialist specifically, not just a general thoracic oncologist, could give you a clearer picture of whether this fits your case.